Update on Complications of Group A Streptococcal Infections

Current Problems in Pediatric and Adolescent Health Care

Volumn 27, Issue 3, 1997, Pages 90-101

  Ayoub, Elia M ^a   Ahmed, Salmon ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; HUMAN; PATHOPHYSIOLOGY; REACTIVE ARTHRITIS; REVIEW; RHEUMATIC FEVER; SEPTIC SHOCK; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES;

ACUTE DISEASE; ARTHRITIS, REACTIVE; HUMANS; RHEUMATIC FEVER; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 0031091060     PISSN: 15385442     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0045-9380(97)80010-2     Document Type: Review

References (87)

1. Johnson DR, Stevens DL, Kaplan EL. Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever or uncomplicated pharyngitis. J Infect Dis 1992;166:374-82.
2. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989;321:1-7.
3. Hauser AR, Stevens DL, Kaplan EL, Schlievert PM. Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes isolates associated with toxic shock syndrome. J Clin Micro 1991;29:1562-7.
4. Norrby-Teglund A, Newton D, Kotb M, Holm SE, Norgren M. Superantigenic properties of the group A streptococcal exotoxin SpeF (MF). Infect Immun 1994;62:5227-33.
5. Mollick JA, Miller GG, Musser JM, Cook RG, Grosssman D, Rich RR. A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with amino-terminal homology to staphylococcal enterotoxins B and C. J Clin Invest 1993;92: 710-9.
6. Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect 1995;1:69-78.
7. Fast DJ, Schlievert PM, Nelson RD. Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production. Infect Immun 1989;57:291-4.
8. Hackett SP, Schlievert PM, Stevens DL. Cytokine production by human mononuclear cells in response to streptococcal exotoxins. Clin Res 1991;39:189A.
9. Murray DL, Ohlendorf DH, Schlievert PM. Staphylococcal and streptococcal superantigens: their role in human diseases. ASM News 1995;61:229-35.
10. Talkington DF, Schwartz B, Black CM, et al. Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun 1993;61:3369-74.
11. Yu CE, Ferretti JJ. Molecular epidemiologic analysis of the type A streptococcal exotoxin (erythrogenic toxin) gene (speA) in clinical Streptococcus pyogenes strains. Infect Immun 1989;57:3715-9.
12. Chaussee MS, Liu J, Stevens DL, Ferretti JJ. Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections. J Infect Dis 1996;173:901-8.
13. Land MA, Bisno AL. Acute rheumatic fever: a vanishing disease in suburbia. JAMA 1983;249:895-8.
14. Shulman ST. The decline of rheumatic fever: what impact on our management of pharyngitis? Am J Dis Child 1984;138: 426-7.
15. Ferrieri P. Acute rheumatic fever: the come-back of a disappearing disease. Am J Dis Child 1987;141:725-7.
16. Kaplan EL. Return of rheumatic fever: consequences, implications, and needs. J Pediatr 1987;111:244-6.
17. Veasy LG, Wiedmeier SE, Orsmond GS, et al. Resurgence of acute rheumatic fever in the intermountain area of the United States. N Engl J Med 1987;316:421-7.
18. Ayoub EM. Resurgence of rheumatic fever in the United States: the changing picture of a preventable disease. Postgrad Med 1992;92:133-42.
19. Zangwill KM, Wald ER, Londino AV Jr. Acute rheumatic fever in western Pennsylvania: a persistent problem into the 1990s. J Pediatr 1991;118:561-3.
20. Loeffler AM, Neches WH, Ortenzo M, Serdy C, Wald ER. Identification of cases of acute rheumatic fever managed on an outpatient basis. Pediatr Infect Dis J 1995;14:975-8.
21. Veasy LG, Tani LY, Hill HR. Persistence of acute rheumatic fever in the intermountain area of the United States. J Pediatr 1994;124:9-16.
22. Kaplan EL, Johnson DR, Cleary PP. Group A streptococcal serotypes isolated from patient and sibling contacts during the resurgence of rheumatic fever in the United States in the mid-1980s. J Infect Dis 1989;159:101-3.
23. Read SE, Reid H, Poon-King T. HLAs and predisposition to the non-suppurative sequelae of group A streptococcal infections. Transplant Proc 1977;9:543-6.
24. Wilson MG, Schweitzer M. Pattern of hereditary susceptibility in rheumatic fever. Circulation 1954;10:699-704.
25. Khanna AK, Buskirk DR, Williams RC, et al. Presence of a non-HLA B cell antigen in rheumatic fever patients and their families as defined by a monoclonal antibody. J Clin Invest 1989;83:1710-6.
26. Ayoub EM, Barrett DJ, Maclaren NK, Krischer JP. Association of class II human histocompatibility leukocyte antigens with rheumatic fever. J Clin Invest 1986;77:2019-25.
27. Anastasiou-Nana MI, Anderson JL, Carlquist JF, Nanas JN. HLA-DR typing and lymphocyte subset evaluation in rheumatic heart disease: a search for immune response factors. Am Heart J 1986;112:992-7.
28. Jhinghan B, Mehra NK, Reddy KS, Taneja V, Vaidya MC, Bhatia ML. HLA, blood groups and secretor status in patients with established rheumatic fever and rheumatic heart disease. Tissue Antigens 1986;27:172-8.
29. Rajapakse CNA, Halim K, Al-Orainey I, Al-Nozha M, Al-Aska AK: A genetic marker for rheumatic heart disease. Br Heart J 1987;58:659-62.
30. Maharaj B, Hammond MG, Bronsthapathy A, Leary WP, Pudifin MB. HLA-A, B, DR, and DQ antigens in black patients with severe chronic rheumatic heart disease. Circulation 1987;76:259-61.
31. Taneja V, Mehra NK, Reddy KS, et al. HLA-DR/DQ and reactivity to B cell alloantigen D8/17 in Indian patients with rheumatic heart disease. Circulation 1989;80:335-40.
32. Guilherme L, Weidebach W, Kiss MH, Snitcowsky R, Kalil J. Association of human leukocyte class II antigens with rheumatic fever or rheumatic heart disease in a Brazilian population. Circulation 1991;83:1995-8.
33. Ozkan M, Carin M, Sonmez G, Senocak M, Ozdemir M, Yakut C. HLA antigens in Turkish race with rheumatic heart disease. Circulation 1993;87:1974-8.
34. Weidebach W, Goldberg AC, Chiarella JM, et al. HLA class II antigens in rheumatic fever: analysis of the DR locus by restriction fragment polymorphism and oligotyping. Hum Immunol 1994;40:253-8.
35. Ayoub EM. The search for host determinants of susceptibility of rheumatic fever: the missing link. Circulation 1984;69: 197-201.
36. Dudding BA, Ayoub EM. Persistence of streptococcal group A antibody in patients with rheumatic valvular disease. J Exp Med 1968;128:1081-98.
37. Shulman ST, Ayoub EM, Victorica BE. Differences in antibody response to streptococcal antigens in children with rheumatic and non-rheumatic mitral valve disease. Circulation 1974;50:1244-51.
38. Appleton RS, Victorica BE, Ayoub EM. Specificity of persistence of antibody to the streptococcal group A carbohydrate in rheumatic valvular heart disease. J Lab Clin Med 1985;105:114-9.
39. Braun DG, Eichmann K, Krause RM. Rabbit antibodies to streptococcal carbohydrates: influence of primary and secondary immunization and of possible genetic factors on the antibody response. J Exp Med 1969;129:809-30.
40. Klapper DG, Kindt TJ. Idiotypic cross-reactions among antistreptococcal antibodies in an inbred rabbit population. Scand J Immunol 1974;3:483-90.
41. Sasazuki T, Kaneoka H, Nishimura Y, Kaneoka R, Hayama M, Ohkuni H. An HLA-linked immune suppression gene in man. J Exp Med 1980;152(2 Pt 2):297S-313S.
42. Cone LA, Woodard DR, Schlievert PM, Tomory GS. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcuspyogenes. N Engl J Med 1987;317:144-9.
43. Ware JC, Foster-Eich W, Ruben EB, Malone JA, Schlievert PM, Gray BM. Streptococcal toxic shock in three Alabama children. Pediatr Infect Dis J 1993;12:765-9.
44. Givner LB, Abramson JS, Wasilauskas B. Apparent increase in the incidence of invasive group A beta-hemolytic streptococcal disease in children. J Pediatr 1991;118:341-6.
45. Wheeler MC, Roe MH, Kaplan EL, Schlievert PM, Todd JK. Outbreak of group A streptococcus septicemia in children: clinical, epidemiologic, and microbiological correlates. JAMA 1991;266:533-7.
46. Chelsom J, Halstensen A, Haga T, Hoiby EA. Necrotizing fascitis due to group A streptococci in western Norway: incidence and clinical features. Lancet 1994;344:1111-5.
47. Rathore MH, Barton LL, Kaplan EL. Suppurative group A β-hemolytic streptococcal infections in children. Pediatrics 1992;89:743-6.
48. Yagupsky P, Giladi Y. Group A beta-hemolytic streptococcal bacteremia in children. Pediatr Infect Dis J 1987;6:1036-9.
49. Vugia DJ, Peterson CL, Meyers HB, et al. Invasive group A streptococcal infections in children with varicella in Southern California. Pediatr Infect Dis J 1996;15:146-50.
50. Bartter T, Dascal A, Carroll K, Curley FJ. Toxic shock syndrome: a manifestation of group A streptococcal infection. Arch Intern Med 1988;148:1421-4.
51. Forni AL, Kaplan EL, Schlievert PM, Roberts RB. Clinical and microbiological characteristics of severe group A streptococcus infections and streptococcal toxic shock syndrome. Clin Infect Dis 1995;21:333-40.
52. Begovac J, Marton E, Lisic M, Beus I, Bozinovic D, Kuzmanovic N. Group A beta-hemolytic streptococcal toxic shock-like syndrome. Pediatr Infect Dis J 1990;9:369-70.
53. Bradley JS, Schlievert PM, Sample TJ Jr. Streptococcal toxic shock-like syndrome as a complication of varicella. Pediatr Infect Dis J 1991;10:77-8.
54. Wilson GJ, Talkington DF, Gruber W, Edwards K, Dermody TS. Group A streptococcal necrotizing fasciitis following varicella in children: case reports and review. Clin Infect Dis 1995;20:1333-8.
55. Doctor A, Harper MB, Fleisher GR. Group A β-hemolytic streptococcal bacteremia: historical overview, changing incidence, and recent association with varicella. Pediatrics 1995;96:428-33.
56. Brogan TV, Nizet V, Waldhausen JHT, Rubens CE, Clarke WR. Group A streptococcal necrotizing fasciitis complicating primary varicella: a series of fourteen patients. Pediatr Infect Dis J 1995;14:588-94.
57. Peterson CL, Vugia DJ, Meyers HB, et al. Risk factors for invasive group A streptococcal infections in children with varicella: a case-control study. Pediatr Infect Dis J 1996;15:151-6.
58. Schlievert PM, Gocke JE, Deringer JR. Group B streptococcal toxic-like syndrome: report of a case and purification of an associated pyrogenic toxin. Clin Infect Dis 1993;17:26-31.
59. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992;14:1201-7.
60. Belani K, Schlievert PM, Kaplan EL, Ferrieri P. Association of exotoxin-producing group A streptococci and severe disease in children. Pediatr Infect Dis J 1991;10:351-4.
61. Schwartz B, Facklam RR, Breiman RF. Changing epidemiology of group A streptococcal infection in the USA. Lancet 1990;336:1167-71.
62. Demers B, Simor AE, Vellend H, et al. Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin Infect Dis 1993;16:792-800.
63. Harnden A, Lennon D. Serious suppurative group A streptococcal infections in previously well children. Pediatr Infect Dis J 1988;7:714-8.
64. Carapetis J, Robins-Browne DM, Shelby-James T, Hogg G. Increasing severity of invasive group A streptococcal disease in Australia: clinical and molecular epidemiological features and identification of a new virulent M-nontypable clone. Clin Infect Dis 1995;21:1220-7.
65. Musser JM, Hauser JM, Kim MH, Schlievert PM, Nelson K, Selander RK. Streptococcus pyogenes causing toxic shocklike syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc Natl Acad Sci U S A 1991;88:2668-72.
66. Holm SE, Norrby A, Berghohn A-M, Norgren M. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J Infect Dis 1992;166:31-7.
67. Norrby-Teglund A, Pauksens K, Holm SE, Norgren M. Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease. J Infect Dis 1994;170:585-91.
68. Lamothe F, D'Amico P, Ghosn P, Tremblay C, Braidy J, Patenaude J-V. Clinical usefulness of intravenous human immunoglobulin invasive group A streptococcal infections: case report and review. Clin Infect Dis 1995;21:1469-70.
69. Norgren M, Norrby A, Holm SE. Genetic diversity in T1M1 group A streptococci in relation to clinical outcome of infection. J Infect Dis 1992;166:1014-20.
70. Sriskandan S, Moyes D, Buttery LK, et al. Streptococcal pyrogenic exotoxin a release, distribution, and role in a murine model of fasciitis and multiorgan failure due to Streptococcus pyogenes. J Infect Dis 1996;173:1399-1407.
71. Davies HD, Matlow A, Scriver SR, et al. Apparent lower rates of streptococcal toxic shock syndrome and lower mortality in children with invasive group A streptococcal infections compared with adults. Pediatr Infect Dis J 1993;13:49-56.
72. The Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. JAMA 1993;269:390-1.
73. Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988;158:23-8.
74. Stevens DL, Bryant AE, Yan S. Invasive group A streptococcal infection: new concepts in antibiotic treatment. Int J Antimicrob Agents 1994;4:297-301.
75. Mahieu LM, Holm SE, Goossens HJ, Van Acker KJ. Congenital streptococcal toxic shock syndrome with absence of antibodies against streptococcal pyrogenic exotoxins. J Pediatr 1995;127:987-9.
76. Barry W, Hudgins L, Donta ST, Pesanti EL. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992;267:3315-6.
77. Dajani AS, Ayoub EM, Bierman FZ, et al. Guidelines for the diagnosis of rheumatic fever: Jones criteria, updated 1992. JAMA 1992;87:302-7.
78. Crea MA, Mortimer EA Jr. The nature of scarlatinal arthritis. Pediatrics 1959;23:879-84.
79. Goldsmith DP, Long SS. Streptococcal disease of childhood - a changing syndrome [abstract]. Arthritis Rheum 1982;25 (suppl):S18.
80. De Cunto CL, Giannini EH, Fink CW, Brewer CJ, Person DA. Prognosis of children with poststreptococcal reactive arthritis. Pediatr Infect Dis J 1988;7:683-6.
81. Gibbas DL, Broussard DA. Poststreptococcal reactive polyarthritis (PSRA): rheumatic fever or not? [abstract] Arthritis Rheum 1986;29(suppl):S92.
82. Birdi N, Allen U, D'Astous J. Poststreptococcal reactive arthritis mimicking acute septic arthritis: a hospital-based study. J Pediatr Orthop 1995;15:661-5.
83. Hubbard WN, Hughes GR. Streptococci and reactive arthritis. Ann Rheum Dis 1982;41:435.
84. Schaffer FM, Agarwal R, Helm J, Gingell RL, Roland JM, O'Neil KM. Poststreptococcal reactive arthritis and silent carditis: a case report and review of the literature. Pediatrics 1994;93:837-9.
85. Rammelkamp CH Jr. Epidemiology of streptococcal infections. Harvey Lect 1956;51:113-42.
86. Aron AM, Freeman JM, Cater S. The natural history of Sydenham's chorea. Am J Med 1965;38:83-95.
87. Dajani A, Taubert K, Fernen P, Peter G, Shulman S, for the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, American Heart Association. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals. Pediatrics 1995;96:758-64.